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Abstract
Background: The aim of this study was to determine the rate of sustained virological response
(SVR) and various factors associated with response rates in chronic hepatitis C infected patients
treated with interferon alpha and ribavirin combination therapy.
Methods: A retrospective review of patients data collected at this Centre from 2001 to 2007 was
performed. Out of 731 consecutive patients 400 patients that fulfilled the study criteria were
evaluated and subsequently treated with a combination of interferon alpha 2b (3 MU
subcutaneously three injections weekly) and ribavirin (800–1200 mg orally daily). Treatment were
administered for either 24 weeks or 48 weeks and patients were followed for an additional 6
months thereafter. End of the treatment response (ETR), SVR and side effects were recorded.
Results:  Out of 400 patients, 394 completed the entire treatment course and six patients
discontinued treatment at month 2. Over 67% responded at the end of treatment and 16% suffered
relapse. Among all treated patients, 47.6% males and 56.7% females had sustained viral response
with a total combined sustained viral response rate of 50.5%. Rapid response was seen in 46.5%
patients. In a multivariate logistic regression analysis, slow virological responders (adjusted OR 2.6
[95% CI 1.9–3.7]), HCV genotype 1&4 (adjusted OR 2.4 [95% CI 1.7–3.5]), pre-treatment viral load
> 0.2 MIU/mL (adjusted OR 2.2 [95% CI 1.8–4.2]), Panjabi ethnic group (adjusted OR 1.6 [95% CI
1.0–3.2]) and Age > 40 years (adjusted OR 1.5 [95% CI 0.9–2.4]) were independent risk factors for
non response. Side effects were usual and tolerable and only 1.5% discontinued the treatment.
Conclusion: The best positive predictor for SVR in this country are: rapid virologic response,
HCV genotype 2 & 3, age < 40 years, ethnic race Pashtoons and pre-treatment viral load < 0.2
million IU/mL.
Background
Hepatitis C virus (HCV) is one of the most important Fla-
viviridae  infections in humans and is the second most
common cause of viral hepatitis [1]. Currently, almost 8–
10% of the Pakistani population (MI., SR. unpublished
data), 2% of the United States of America (USA) popula-
tion, and an estimated 170 million people worldwide are
HCV carriers [2]. Chronic HCV infection frequently
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results in liver cirrhosis and is associated with an elevated
risk of developing hepatocellular carcinoma [3]. Although
symptoms may be mild for decades, 20% of persistently
infected individuals may eventually develop serious liver
disease including cirrhosis and liver cancer [2]. The only
effective treatment is based on interferon alpha (IFN-α).
Treatment with either IFN-α alone or in combination with
ribavirin leads to a sustained virological response (SVR) in
20% to 56% of patients with chronic hepatitis C [4,5]. The
combination of interferon and ribavirin is the preferred
treatment and achieves a better response than interferon
or ribavirin alone [6]. However, nonresponse to this ther-
apy remains common and is associated with several fac-
tors such as HCV genotype, duration of a person's HCV
infection and HCV viral load in addition to host factors
such as sex, HLA type and cytokine polymorphisms [7,8].
Patient age, grade of liver inflammation and ethnicity
have also been shown to influence response to therapy
[9,10]. The strongest predictors for a SVR to treatment is
the HCV genotype, with HCV genotype 1 (HCV-1) being
the least sensitive to IFN-α based therapy [11,12].
Several studies are available on the response rates to com-
binatorial IFN-α/ribavirin treatment of hepatitis C in Paki-
stan [13,14], however, these do not describe positive and
negative predictors for the SVR rates. The aim of this study
was to determine the efficacy and safety of a 24 weeks or 48
weeks treatment with IFN-α plus ribavirin in patients with
chronic hepatitis C genotypes none-1 and 1 respectively
and to identify factors that impaired response to antiviral
therapy. We focused our study on naïve patients that had
not previously received antiviral treatment and who pre-
sented with HCV genotypes non-1 and 1.
Methods
Patients
A retrospective analysis was performed on data collected
from 731 patients with chronic HCV infection screened
between 2001 and 2007 at multiple clinics throughout
Pakistan. Of the 731 consecutive screened patients, 400
patients (280 male, 120 female, mean age 38 years [range,
16–70 ± SD] years) were chronically infected with various
HCV subtypes and had not received antiviral treatments
previously. These 400 patients fulfilled the study criteria
and were enrolled for antiviral therapy. A total of 331
patients were excluded as either they were unwilling to
participate (n = 119) or failed to meet inclusion criteria
for the study (n = 212). Patients were enrolled from prov-
inces of Punjab (Panjabi; 299), North West Frontier Prov-
ince (Pashtoons; 78), Sindh (Sindhi; 11) and Balochistan
(Balochi; 12). Probable transmission risk factors were pre-
vious major/minor surgery (20%), transfusion of blood
or blood products (2%), dental surgery (10%), or spo-
radic (60%). The estimated duration of infection varied
from 6 months to 20 years.
Diagnosis, inclusion and exclusion criteria
The diagnosis of chronic hepatitis C was based on ele-
vated serum transaminase levels for at least 6 months and
the consistent detection of serum HCV RNA. Anti-HCV
antibodies (3rd generation ELISA) were present in each
patient. Prior to the start of the treatment, patients com-
plete blood count (CBC) were measured and patients
were required to have haemoglobin levels above 13 g/dL
in males and 12 g/dL in females and platelet counts above
80,000. Patients were also required to have persistently
elevated alanine aminotransferase (ALT), white blood cell
count greater than 3.0/mm3, normal serum bilirubin,
albumin, creatinine and thyroxin levels. Furthermore the
patients were required to be negative for hepatitis B sur-
face antigen, and not suffering from decompensate liver
disease, autoimmune disorders, or a history of depression
and/or cardiac diseases. Patients that were under 18 years
or above 70 years of age and pregnant females were also
excluded from the studies.
Measurement of HCV RNA and HCV genotyping
Quantitative detection of HCV RNA in patient sera during
pre-treatment, treatment and post-treatment were per-
formed using real-time PCR (SmartCycler II, Cepheid,
USA) with an internal RNA standard derived from the 5'
UTR. Genotyping of HCV was performed in pre-treatment
sera as described previously [15]. All measures suggested
by Kwok and Higuchi [16] to prevent sample contamina-
tion were strictly adhered to.
Treatment
All patients with HCV 2a-b, 3a-d, 5a, 6a or with mixed
infection of these genotypes received 3 subcutaneous
injections per week of 3 MU recombinant IFN-α plus rib-
avirin (10 mg/day/kg body weight) for a total of 24 weeks.
All patients with HCV genotypes 1a-c, 4 or those with
mixed infections of these genotypes received 3 subcutane-
ous injection per week of 3 MU recombinant IFN-α plus
ribavirin administered orally (1,000 mg/day for patients ≤
75 kg body weight or 1,200 mg/day for patients > 75 kg
body weight) for 48 weeks. Informed consent (printed in
local language) was obtained from each patient and the
Ethics Committee of the Centre approved this study.
Patients monitoring
All patients that fulfilled the study criteria were monitored
for HCV RNA and ALT during and after treatment. Efficacy
of treatment was assessed with normalization of ALT and
absence of serum HCV RNA measured at week 4, 8, 12 and
24 and being undetectable at the end of the treatment at
24 or 48 weeks which constituted end of treatment
response and at the end of follow up at 12 or 18 months
which constituted the sustained viral response for patients
with genotypes non-1 and 1 respectively. Adverse effects
were monitored during each follow up visit. The study wasBMC Gastroenterology 2009, 9:5 http://www.biomedcentral.com/1471-230X/9/5
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initiated in May 2001 and all the follow-ups were com-
pleted by June 2007. A number of study end-points were
defined, based upon the copy number of HCV RNA in
patient sera. End of treatment response (ETR) was defined
as undetectable HCV RNA (< 100 copies/mL) at the end
of treatment. Sustained virologic response (SVR) was
undetectable HCV RNA 6 months after the end of treat-
ment and non responders were those who were with
detectable HCV RNA at the end of treatment. Patient
relapse was defined as those whose HCV RNA was unde-
tectable at the end of treatment but reappeared within 6
months of cessation of treatment. Rapid virologic
response (RVR) was defined as undetectable HCV RNA
following an initial 4 weeks of treatment.
Statistical analysis of the generated data
Clinical and biochemical characteristics of patients are
expressed as a mean or median, with a standard deviation
as appropriate. Summary statistics were calculated using
SPSS (v10.0 SPSS Inc.). The results for all variables were
given in the form of rates (%.). Chi-square and Fishers
Exact test was used to measure association amongst cate-
gorical variables. P-values less than 0.05 were considered
significant. Multivariate logistic regression analysis was
performed to identify factors that were associated with
non response to therapy. Variables associated with relapse
in univariate analysis (P < 0.1) were entered into the
model. Potential confounders were tested before selecting
the final model by entering non-significant variables into
the selected multivariate model and determined their
effect on the odds ratios of the independent variables.
Results
Study enrolments and disposition of patients
Four hundreds patients with chronic HCV who fulfilled
the study criteria were enrolled for this study from an ini-
tial pool of 731 patients (Figure 1). Of these 400 patients,
280 were males and 120 females. Six patients discontin-
ued treatment due to severe side effects experienced
within the second month of treatment. Four patients dis-
played a rapid virological response with negative PCR at
the time of discontinuation of treatment. Two hundred
and seventy six males and 118 females, making a total of
394 patients completed the entire course of treatment. A
total of 57 patients had liver biopsies out of which 16 had
liver cirrhosis and rest of the 41 had stage 1–3 of fibrosis.
The demographic characteristics of the patients treated are
shown in Table 1. A total of 331 patients were excluded
from the study either they were unwilling to participate in
the study (n = 119) or failed to meet inclusion criteria of
the study (n = 212) such as low haemoglobin level (below
13 g/dL in men and 12 g/dL in women), and/or low plate-
let counts (below 80,000) and/or white blood cell count
less than 3.0/mm3, abnormal serum bilirubin, albumin,
creatinine and thyroxin levels. Six patients were also pos-
itive for hepatitis B surface antigen, four were with decom-
pensating liver disease, five were with autoimmune
disorders and 23 had history of depression and cardiac
diseases. Pregnant women (n = 9), patients < 18 years or
> 70 years (n = 7) and with persistently normal ALT levels
(n = 61) were also excluded from the study.
Virologic response
Out of 400 patients, 268 patients (67%) showed end of
treatment response (ETR) and 202 (50.5%) patients
achieved a sustained virological response (SVR). Sixty six
(16.5%) patients were HCV-RNA negative at the end of
treatment but relapsed thereafter. One hundred and thirty
two (33%) patients were virologic nonresponders show-
ing detectable HCV RNA at the end of treatment. Rapid
virological response was seen in 186 (46.5%) patients.
Out of sixteen patients who had cirrhosis on the liver
biopsy, 10 were males and 6 were females. Half of these
patients had end of treatment response but all were
relapsed giving no sustained viral response in these
patients.
Virologic response in different ethnic groups
An ethnic difference was seen in both ETR and SVR rates.
In ethnic groups Pashtoon, Panjabi, Sindhi and Balochi
the rates of SVR were 69.2%, 45.5%, 45.5% and 50%
respectively. The rates of SVR are significantly higher in
ethnic group Pashtoon compared with Panjabi, Sindhi
and Balochi patients (P = 0.026).
Predictors of sustained virologic response
Several factors were found to be predictors of SVR in this
study. These were HCV genotype, pre-treatment HCV RNA
levels, age, presence or absence of cirrhosis, rapid viro-
logic or delayed virologic responses and ethnicity. Tables
2 summarize the ETR, SVR or no response (NR) results in
patients with different HCV genotypes. It is clear from the
data of the present study that the rates of ETR and SVR are
different among patients with different genotypes. The
highest SVR was seen in patients with HCV genotype 2
(69.7%) followed by genotype 3 having patients (57.3%)
and lowest SVR in genotype 1 infected patients (24.3%).
Table 3 shows rates of ETR, SVR and NR in patients with
different age groups. Rates of ETR and SVR are very high in
patient ≤ 20 years (66.7%) and very low (0%–27%) in age
group ≥ 50 years. All the variables associated with SVR in
chronic HCV patients studied in the course of the present
study are shown in Table 4. The SVR was found signifi-
cantly higher in patients below 40 years of age compared
to those above 40 years (P = 0.022), having non-1 geno-
type than patients with genotype 1 & 4 (P < 0.001),
patients with pre-treatment viral load of < 0.2 million IU/
mL compared with pre-treatment viral load of > 0.2 mil-
lion IU/mL blood (P < 0.001), rapid virologic responseBMC Gastroenterology 2009, 9:5 http://www.biomedcentral.com/1471-230X/9/5
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Study enrollment and disposition of patients Figure 1
Study enrollment and disposition of patients.
331 patients were excluded from the 
study because they failed to meet 
inclusion criteria or were unwilling to 
participate 
Total 731 patients with chronic HCV were 
screened 
400 patients were assigned to treatment 
5 patients discontinued 
treatment due to severe side 
effect at month 2  
All 310 patients completed 24 
weeks of follow-up 
310 patients completed 24 weeks of
treatment 
315 patients that had HCV genotypes 2a-b,
3a-d, and with mixed infection of these 
genotypes received 3MU recombinant 
IFN-Į three times weekly subcutaneously 
and ribavirin (10 mg/day/kg body weight) 
for a total of 24 weeks 
1 patient discontinued 
treatment due to severe side 
effect at month 2  
All 84 patients completed 24 weeks 
of follow-up 
84 patients completed 48 weeks of 
treatment 
85 patients with HCV genotypes 1a-c, 4 or 
patients with mixed infections of these 
genotypes were treated with 3 MU IFN-Į 3 
times weekly for 48 weeks plus ribavirin 
orally(1,000 mg/d in patients with 75 kg 
body weight or 1,200 mg/d in patients 
above 75 kg body weight)BMC Gastroenterology 2009, 9:5 http://www.biomedcentral.com/1471-230X/9/5
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(RVR) achiever than non-RVR achiever (P = 0.04), absence
of cirrhosis compared to its presence (P = 0.002) and in
ethnic groups Pashtoon compared with Panjabi patients
(P = 0.026). Pre-treatment ALT levels had no predictive
role in treatment response rate. No significant difference
was seen for ETR and SVR in male and female patients.
Multivariate logistic regression analysis indicated that non
achiever of RVR (adjusted OR 2.6 [95% CI 1.9–3.7]), HCV
genotype 1&4 (adjusted OR 2.4 [95% CI 1.7–3.5]), pre-
treatment viral load > 0.2 MIU/mL (adjusted OR 2.2 [95%
CI 1.8–4.2]), Panjabi ethnic group (adjusted OR 1.6 [95%
CI 1.0–3.2]) and Age > 40 years (adjusted OR 1.5 [95% CI
Table 1: Demographic characteristics of treated patients (N = 400).
Characteristics Genotype 1
(N = 70)
Genotype 2
(N = 33)
Genotype 3
(N = 260)
Other Genotypes
(N = 6) *
Mixed Genotypes
(N = 31)†
Sex-No. (%)
Male 47 (67.1) 22 (66.7) 185 (71.2) 6 [100] 20 (64.5)
Female 23 (32.9) 11 (33.3) 75 (28.8) 0 [0] 11 (35.5)
Age range-years
Mean age (Y) 25–70 21–68 18–55 20–57 21–60
± SD‡ 50 ± 9.5 48 ± 9.0 45 ± 10.2 49 ± 9.8 46 ± 8.4
Ethnic group-No. (%)
Panjabi 50 (71.4) 21 (63.6) 203 (78.1) 4 (66.7) 21 (67.7)
Pashtoons 15 (21.4) 10 (30.3) 41 (15.8) 2 (33.3) 10 (32.3)
Balochi 3 (4.2) 1 (3.0) 7 (2.7) 0 0
Sindhi 2 (2.9) 1 (3.0) 9 (3.4) 0 0
Pre-treatment HCV RNA level
< 200,000 IU/mL 22 (31.4%) 11 (33.3) 71 (27.3) 1 (16.7) 4 (12.9)
> 200,000 IU/mL 48 (68.6) 22 (66.7) 189 (72.7) 5 (83.3) 27 (87.1)
Cirrhosis-No (%)
Present 3 (4.3) 2 (6.1) 9 (3.5) 0 [0] 2 (6.5)
Absent/unknown 67 (95.7) 31 (93.9) 251 (96.5) 6 [100] 29 (93.5)
*Of the patients with other genotypes, 4 had HCV genotype 4 and one each was with genotype 5a and 6a.
†Out of 31 patients with mixed genotypes, 13 were with genotypes 3a+3b; 4 with 2a+3b; 3 each with 2a+3a & 1a+1b, 2 each with 1a+3a & 3a+4; 1 
each with 1a+3c, 1b+2a, 1c+3b & 1c+3c.
‡SD, standard deviation.
Table 2: Rates of NR*, ETR† and SVR‡ in patients infected by different HCV genotypes to interferon plus ribavirin therapy (N = 400).
HCV GENOTYPE TREATED PATIENTS NR* ETR† SVR‡
1 (a, b, c) 70 42 (60%) 28 (40%) 17 (24.3%)
2 (a, b) 33 5 (15.2%) 28 (84.8%) 23 (69.7%)
3 (a, b, c, d) 260 65 (25%) 195 (75%) 149 (57.3%)
Others (4, 5a, 6a) 6 2 (33.3) 4 (66.7%) 3 (50%)
Mixedψ 31 18 (58.1%) 13 (41.9%) 10 (32.3%)
Total 400 132 (33%) 268 (67%) 202 (50.5%)
*NR, Non-responders, defined as detectable HCV RNA at the end of anti-viral treatment.
†ETR, End of treatment response, defined as undetectable HCV RNA at the end of treatment.
‡SVR-Sustained virologic response, defined as undetectable HCV RNA 24 weeks after end of anti-viral treatment.
ψOf the 31 patients with mixed genotypes, 13 were with genotypes 3a+3b; 4 with 2a+3b; 3 each with 2a+3a & 1a+1b, 2 each with 1a+3a & 3a+4; 1 
each with 1a+3c, 1b+2a, 1c+3b & 1c+3c.BMC Gastroenterology 2009, 9:5 http://www.biomedcentral.com/1471-230X/9/5
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0.9–2.4]) were independent risk factors for low rates of
SVR (Table 5).
Safety
All patients tolerated the treatment well except for six
patients who discontinued due to severe side effects. Dos-
age reduction of ribavirin was made in 10 patients due to
drop in haemoglobin level below 10 g/dL and the inter-
feron units were reduced in 5 patients due to drop in leu-
kocytes counts below 2,000 and platelet count below
50,000. All these patients completed the treatment with
adjusted dosage. The side effects were mostly influenza-
like syndrome, which occurred in more than 80%
patients. Gastrointestinal, psychiatric, dermatological
symptoms and other side effects were tolerated. The side
effects observed in patients during therapy are detailed in
Table 6.
Discussion
Our study of patients infected with HCV shows that the
overall end of treatment response rates to interferon plus
ribavirin therapy is very high (67%) in this country. In a
considerable proportion of patients (16%) however, viro-
logic relapse occurred after the completion of therapy in
the follow up period. This relapse rate is very high as com-
pared to that reported by Khokhar and Co-workers [17] in
Pakistani patients (only 4% relapse rate) but is very low
compared to that reported by Sarrazin et al., [18] that was
43%. Similarly, John et al., [19] have reported a response
rate of 53% to combination therapy for 6 months with
sustained virological response of 31%. The low response
rate reported by Sarrazin et al., and John et al., may be due
to the fact that genotype 1b was predominant in their
study which is associated with severe clinical course of the
disease and a decreased response to treatment. Con-
versely, in Pakistan the predominant genotype is 3a,
which has a slower progression and a better response to
treatment [20].
A number of viral and host factors have been identified
during the course of the present study that may help to
predict response rates of current antiviral therapy. Our
data suggest that the patients slow/rapid virologic
response rate, their pre-treatment HCV viral load, age,
stage of fibrosis, gender, ethnicity and HCV genotypes are
factors that may play an important role in determining
response rates to interferon plus ribavirin treatment. The
most important of these factors appears to be the achieve-
ment of undetectable level of HCV-RNA in serum by week
4, the HCV genotype and pre-treatment viral load. This
data suggest that patients with a rapid virologic response
(RVR) had a significantly higher sustained virologic
response (SVR) rate (P < 0.05); in more than 85% of cases
RVR occurred with SVR. These findings support a recent
study that suggests high rates of SVR in patients shown
RVR within 16 weeks and 24 weeks of therapy [21]. As
expected, it was also observed in the present study that
rate of SVR differed among patients with different HCV
genotypes, with higher SVR observed with HCV genotypes
2 and 3. This finding in the Pakistani population confirms
previously reported work that shows a better response to
IFN-alpha treatment in patients with HCV genotypes 2
and 3 [8,22,23] from other parts of the World. An interest-
ing finding of the present study is that the SVR rate is sig-
nificantly higher in patients with a pre-treatment viral
load of less than 200,000 IU per mL than patients with
pre-treatment viral load of greater than 200,000 IU/mL.
Several other recent studies have shown an inverse rela-
tionship between sustained virologic response rates and
pre-treatment viral load [21,24].
Table 3: Rates of NR*, ETR† and SVR‡ in HCV infected patients of different Age groups to interferon plus ribavirin therapy (N = 400).
S. No. AGE GROUP TOTAL PATIENTS NR (%) ETR (%) SVR (%)
1 ≤ 20 Years 9 1 (11.1%) 8 (88.9%) 6 (66.7%)
2 21–30 Years 91 27 (29.7%) 64 (70.3%) 50 (54.9%)
3 31–40 Years 154 48 (31.2%) 106 (68.8%) 88 (57.1%)
4 41–50 Years 107 40 (37.4%) 67 (62.6%) 48 (44.9%)
5 51–60 Years 37 14 (37.8%) 23 (62.2%) 10 (27.1%)
6 > 60 Years 2 2 (100%) 0 0
Total 400 132 (33%) 268 (67%) 202 (50.5%)
*NR, Non-responders, defined as detectable HCV RNA at the end of anti-viral treatment.
†ETR, End of treatment response, defined as undetectable HCV RNA at the end of treatment.
‡SVR-Sustained virologic response, defined as undetectable HCV RNA 24 weeks after end of anti-viral treatment.BMC Gastroenterology 2009, 9:5 http://www.biomedcentral.com/1471-230X/9/5
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Perhaps the most interesting and important finding of the
present study is the observation that response rates are sig-
nificantly higher (P = 0.026) in ethnic Pashtoon as com-
pared to Panjabi. Race has also been shown to influence
response to therapy by other researchers [9,10]. This sug-
gests that Panjabi race is an independent risk factor for the
decreased rate of response to treatment of HCV infection.
These data need to be conformed by further studies with
larger numbers of Pashtoon patients. The baseline charac-
teristics of Pashtoon and Panjabi patients were similar
however we were unable to assess differences in body
mass index and incidence of diabetes mellitus that may
play a role in interferon non-responsiveness. Similar rates
of SVR have been reported in Indian Panjabi 53% [25]
compared to 45.5% seen in the present study. The 7.5%
greater response rate seen in Indian Panjabi race may be
due to the administration of pegylated interferon and rib-
avirin for treatment. Our study further shows that younger
patients have higher response rates to antiviral therapy
than older patients (P < 0.001) in agreement with previ-
ous studies [21-23]. Another important finding of the
present study is that patients with cirrhosis had 0% SVR
rates even though 85% patients with cirrhosis enrolled in
this study had ETR. This observed ETR is much better than
previously reported response but unfortunately all of our
patients with cirrhosis were relapsed soon after treatment
was discontinued.
All patients enrolled in this study tolerated the treatment
well and the side effects were in line with that previously
reported [26]. Six of our patients did develop psychosis
and had to discontinue treatment after 2 months of treat-
ment, relapsing soon thereafter. Though side effects of the
combination regimen are additive not synergistic, they
Table 4: Variables associated with rates of SVR‡ in chronic HCV patients treated with interferon plus ribavirin standard therapy (N = 400).
Variable Total No. of treated patients
(n = 400)
Achieved SVR
(n = 202)
SVR rate, % P-value
Age, years
≤ 40 251 144 57.4 0.022
> 40 149 58 38.9
Sex
Female 120 68 56.7 NS
Male 280 134 47.8
Ethnic group
Pushtoon 78 54 69.2 0.026
Punjabi 299 136 45.5
Sindhi 11 5 45.5
Baloch 12 6 50.0
Pre-treatment viral load
< 0.2 MIU/mL 291 173 59.5 0.001
> 0.2 MIU/mL 109 29 26.6
Rapid virological response
Achieved 186 139 74.7 0.04
Not achieved 214 63 29.4
HCV genotype
2, 3 or mixed with 2&3 315 181 57.5 0.005
1, 4, 5, 6 or mixed 85 21 24.7
Cirrhosis†
Present 16 0 0 0.021
Absent 41 23 56.09
Pre-treatment ALT
Moderately high 239 121 50.6 NS
Very high 161 81 50.3
‡SVR-Sustained virologic response, defined as undetectable HCV RNA 24 weeks after end of anti-viral treatment.
†The number of participants does not add up to400 for one variable due to it being not applicable.BMC Gastroenterology 2009, 9:5 http://www.biomedcentral.com/1471-230X/9/5
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generally do not limit the safe use of this therapy. Appro-
priate recognition and management of side effects will
both improve therapeutic response and avoid unneces-
sary morbidity and mortality [27].
Conclusion
In conclusion our study shows that twenty-four weeks
combination treatment with interferon-α2b and ribavirin
in patients with genotypes 2 and 3 may be as useful as
PEG-interferon plus ribavirin for sustained virological
response. Patients with RVR, low pre-treatment viral load,
HCV genotypes 2 & 3, age < 40 years and ethnic group
Pashtoon appear to have the highest probability of ETR
and SVR.
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